ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 479,40
-0,68%
Dow Jones
39 118,86
-0,12%
DAX
18 235,45
0,17%
Brent Oil
84,85
0,00%
Bitcoin
61 305,77
0,68%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Imunon Inc (IMNN)

  7. Imunon Inc (IMNN) Actualités

IMNN

Imunon (IMNN)

Imunon Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:IMNN
DateHeureSourceTitreSymboleSociété
24/06/202414h30GlobeNewswire Inc.IMUNON Announces Database Lock for Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian CancerNASDAQ:IMNNImunon Inc
14/06/202412h15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMNNImunon Inc
13/06/202415h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IMNNImunon Inc
10/06/202420h00Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:IMNNImunon Inc
05/06/202414h30GlobeNewswire Inc.First Participants Vaccinated in IMUNON’s IMNN-101 Phase 1 Clinical TrialNASDAQ:IMNNImunon Inc
23/05/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:IMNNImunon Inc
15/05/202422h16Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:IMNNImunon Inc
15/05/202414h30GlobeNewswire Inc.Abstract on Phase 2 Study with IMUNON’s IMNN-001 Plus Bevacizumab Accepted for Presentation at the American Society of Clinical Oncology Annual MeetingNASDAQ:IMNNImunon Inc
13/05/202415h00GlobeNewswire Inc.IMUNON Announces Site Activation for IMNN-101 Phase 1 Vaccine StudyNASDAQ:IMNNImunon Inc
13/05/202414h10Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IMNNImunon Inc
13/05/202414h00GlobeNewswire Inc.IMUNON Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:IMNNImunon Inc
08/05/202414h00GlobeNewswire Inc.IMUNON Appoints Director Dr. Stacy R. Lindborg as President and CEONASDAQ:IMNNImunon Inc
06/05/202417h00GlobeNewswire Inc.IMUNON to Hold First Quarter 2024 Financial Results and Business Update Conference Call on Monday, May 13, 2024NASDAQ:IMNNImunon Inc
18/04/202414h30GlobeNewswire Inc.IMUNON’s IND Application Cleared to Begin Human Testing of IMNN-101NASDAQ:IMNNImunon Inc
11/04/202414h00GlobeNewswire Inc.IMUNON Reports Compliance with Nasdaq Listing RequirementsNASDAQ:IMNNImunon Inc
28/03/202413h00GlobeNewswire Inc.IMUNON Reports 2023 Financial Results and Provides Business UpdateNASDAQ:IMNNImunon Inc
25/03/202413h30GlobeNewswire Inc.IMUNON Receives $1.3 Million from Sale of its New Jersey Net Operating LossesNASDAQ:IMNNImunon Inc
21/03/202422h00GlobeNewswire Inc.IMUNON to Hold 2023 Financial Results and Business Update Conference Call on Thursday, March 28, 2024NASDAQ:IMNNImunon Inc
13/03/202413h00GlobeNewswire Inc.IMUNON Files IND Application to Begin Human Testing of IMNN-101NASDAQ:IMNNImunon Inc
12/03/202422h00GlobeNewswire Inc.IMUNON Announces Leadership ChangeNASDAQ:IMNNImunon Inc
29/02/202414h30GlobeNewswire Inc.Independent Lab Confirms Immunogenicity and Protection with IMUNON’s IMNN-101 in a Live Virus Challenge Against SARS-CoV-2 Variant XBB.1.5NASDAQ:IMNNImunon Inc
27/02/202414h30GlobeNewswire Inc.Memorial Sloan Kettering Cancer Center Now Enrolling Patients in Phase 1/2 Clinical Trial of IMUNON’s IMNN-001 in Combination with Bevacizumab in Advanced Ovarian CancerNASDAQ:IMNNImunon Inc
22/02/202414h00GlobeNewswire Inc.IMNN-101 Preclinical Data in SARS CoV-2 Published in Peer-Reviewed Journal VaccineNASDAQ:IMNNImunon Inc
09/02/202422h09Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:IMNNImunon Inc
20/12/202323h15Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:IMNNImunon Inc
11/12/202314h30GlobeNewswire Inc.IMUNON Appoints Dr. Sebastien Hazard as Chief Medical Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:IMNNImunon Inc
14/11/202315h00GlobeNewswire Inc.IMUNON’s VP of R&D to Present at the Vaccines Summit-2023NASDAQ:IMNNImunon Inc
14/11/202314h00GlobeNewswire Inc.IMUNON Reports Third Quarter 2023 Financial Results and Provides a Business UpdateNASDAQ:IMNNImunon Inc
07/11/202314h30GlobeNewswire Inc.IMUNON to Hold Third Quarter 2023 Financial Results and Business Update Conference Call on Tuesday, November 14, 2023NASDAQ:IMNNImunon Inc
23/10/202314h30GlobeNewswire Inc.IMUNON’s Chief Science Officer to Present at the 3rd International Vaccines CongressNASDAQ:IMNNImunon Inc
 Showing the most relevant articles for your search:NASDAQ:IMNN

Dernières Valeurs Consultées

EU
RNO
Renault
EU
ACA
Credit Agricole
EU
VIV
Vivendi
NASDAQ
AMZN
Amazon.com
NASDAQ
NVDA
NVIDIA
EU
BN
Danone
SPI
SP500
S&P 500
EU
VK
Vallourec
FTSE
UKX
FTSE 100
EU
DG
Vinci
EU
ORA
Orange
NYSE
NKE
Nike
EU
CS
Axa
EU
LR
Legrand
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés